The ARPA-H PROactive Solutions for Prolonging Resilience (PROSPR) program aims to use predictive models to match treatments with changing tumor biology and prevent disease progression. 

Funding for awardees varies in amount and is contingent upon the recipient meeting aggressive milestones specific to their project.

Performer teams are led by:  

• Stanford University in Palo Alto, CA will harmonize the vast existing health datasets collected by multiple institutions to generate a healthspan score (PROSPR-IC score). They will test the accuracy and intervenability of this score in a 1-year lifestyle intervention, which will be supported by an in-home digital health assessment technology they develop.  
• The University of Texas Health Science Center at San Antonio in San Antonio, TX will establish a regulatory path for testing the efficacy of therapeutics for aging by conducting a phase 3 hybrid trial to repurpose three FDA-approved drugs: SGLT2 inhibitor, rapamycin, and semaglutide.  
• Columbia University Mailman School of Public Health in New York, NY, aims to identify biomarkers that are responsive to interventions that improve aging outcomes in humans by performing combined analysis of multiple, previously performed intervention trials.  
• Apollo Alpha in St. Petersberg, FL will test whether an orally bioavailable compound that crosses the blood–brain barrier and targets energy homeostasis, lipid metabolism, and inflammation will improve aging outcomes. 
• Cambrian BioPharma in New York, NY will test whether a daily, oral, novel rapamycin analog will improve aging outcomes.  
• Linnaeus Therapeutics in Haddonfield, NJ, will test whether a compound with an established safety profile, demonstrated cardiometabolic benefits, and once-daily dosing improves aging outcomes. 
• The University of Rochester in Rochester, NY, will evaluate whether a compound with an established human safety profile and high relative potency within its class, can improve aging-related outcomes.